Core Viewpoint - Heng Rui Medicine announced the approval of clinical trials for SHR-1905 injection by the National Medical Products Administration, indicating a significant step in the development of a new therapeutic option targeting inflammation [1] Group 1: Company Developments - The subsidiary Guangdong Heng Rui Medicine Co., Ltd. received the clinical trial approval notice for SHR-1905 injection [1] - SHR-1905 is a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), which plays a role in blocking the release of inflammatory cytokines [1] Group 2: Product Information - SHR-1905 injection aims to inhibit downstream inflammatory signaling pathways, ultimately improving inflammatory conditions and controlling disease progression [1]

Core Viewpoint - Heng Rui Medicine's subsidiary, Guangdong Heng Rui Medicine Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-1905 injection, which is expected to commence soon [1] Group 1: Company Developments - The SHR-1905 injection is a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), designed to block the release of inflammatory cytokines [1] - The mechanism of SHR-1905 involves inhibiting downstream inflammatory signaling pathways, ultimately improving inflammatory conditions and controlling disease progression [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) announced that its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Heng Rui Medicine Co., Ltd., have received approval from the National Medical Products Administration for the clinical trial of SHR-A2102, which will commence shortly [1] Group 1: Product Development - SHR-A2102 is a self-developed antibody-drug conjugate (ADC) targeting Nectin-4, with a payload of topoisomerase I inhibitor (TOP1i) [1] - Research indicates that high expression of Nectin-4 in tumors is closely related to tumor progression and poor prognosis [1]

Core Viewpoint - Heng Rui Medicine's subsidiary has received approval for clinical trials of SHR-1905 injection, a monoclonal antibody targeting TSLP, which aims to improve inflammation and control disease progression [1] Group 1: Company Developments - Heng Rui Medicine (600276.SH) announced that its subsidiary, Guangdong Heng Rui Medicine Co., Ltd., has received the clinical trial approval notice from the National Medical Products Administration for SHR-1905 injection [1] - The SHR-1905 injection is designed to block the release of inflammatory cytokines and inhibit downstream inflammatory signaling [1] Group 2: Market Context - There is a similar product, Tezepelumab (AstraZeneca/Amgen, marketed as Tezspire), which has been approved and is projected to generate approximately $1.22 billion in global sales in 2024 according to EvaluatePharma database [1]

Core Viewpoint - Heng Rui Medicine has received clinical trial approval for three drug candidates, indicating progress in its research and development pipeline [1] Group 1: Clinical Trial Approvals - The company’s subsidiaries have received approval from the National Medical Products Administration for clinical trials of SHR-A2102, Adebeli monoclonal antibody injection, and SHR-1802 [1] - SHR-A2102 is an antibody-drug conjugate targeting Nectin-4, with only one similar product approved globally [1] - SHR-1802 is a humanized monoclonal antibody developed by the company, with no similar products approved in China [1] - Adebeli monoclonal antibody injection is a humanized anti-PD-L1 monoclonal antibody developed by the company [1]

Core Insights - The company announced that its subsidiaries Suzhou Shengdiya, Shanghai Hengrui, and Shanghai Shengdi Pharmaceutical received clinical trial approval from the National Medical Products Administration for three injectable drugs [1] Group 1: Drug Development - SHR-A2102 is an antibody-drug conjugate developed by the company, with a cumulative R&D investment of approximately 225 million yuan [1] - SHR-1802 is a humanized monoclonal antibody, with a cumulative R&D investment of about 62.09 million yuan [1] - Adebali monoclonal antibody injection is a humanized anti-PD-L1 monoclonal antibody, with a cumulative R&D investment of around 939 million yuan [1] Group 2: Clinical Research - These drugs will be used in Phase I B/II clinical studies for advanced solid tumors [1]

Core Viewpoint - Heng Rui Medicine (01276.HK) announced a share buyback of 170,000 A-shares at a total cost of RMB 11.35 million, with a buyback price range of RMB 66.18 to 67.01 per share [1] Related Events - Heng Rui Medicine (01276.HK) conducted a buyback on October 13, spending RMB 11.35 million to repurchase 170,000 A-shares [1] - The company plans to hold a board meeting on October 27 to approve its quarterly performance [1]

Core Viewpoint - Heng Rui Medicine (01276) announced a share buyback of 170,000 A-shares at a cost of 11.35 million yuan on October 13, 2025 [1] Summary by Category - **Company Actions** - The company plans to repurchase shares, indicating confidence in its stock value and future prospects [1] - **Financial Details** - The total expenditure for the buyback is 11.35 million yuan, which translates to approximately 1.135 million dollars [1]

Core Viewpoint - Heng Rui Medicine (600276) announced a share buyback of 170,000 A-shares at a cost of 11.35 million yuan on October 13, 2025 [1] Group 1 - The company is actively engaging in share repurchase to enhance shareholder value [1] - The total expenditure for the buyback amounts to 11.35 million yuan [1] - The number of shares repurchased is 170,000 [1]

格隆汇10月13日丨恒瑞医药(01276.HK)宣布，董事会会议将于2025年10月27日(星期一)举行，藉以(其中 包括)考虑及批准本公司及其附属公司截至2025年9月30日止九个月的季度业绩及其发布。 ...